Correction to Empliciti Approval Story
November 30 2015 - 12:56PM
Dow Jones News
The FDA approved Empliciti to be used in combination with two
other FDA-approved treatments, dexamethasone and Revlimid. "FDA
Approves New Blood-Cancer Drug Empliciti," published at 11:38 a.m.
ET, and an update, incorrectly said Darzalex was used in this drug
cocktail.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 30, 2015 12:41 ET (17:41 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2023 to Mar 2024